Blog Header

By: Oncostellae

25 Mar 2019
Oncostellae participates at the BIO-Europe partnering conference in Vienna

febrero 26, 2019

Oncostellae will assist at the 13th Annual International Partnering Conference BIO-Europe Spring that will be celebrated from 25 to 27 of…

Read More
10 Dec 2018
GI-restricted Jak3/Tyk2 inhibitor OST-122 well tolerated in clinical phase Ia study

febrero 24, 2019

OST-122, a novel, gut-restricted Jak3/Tyk2 inhibitor for the local treatment of gastrointestinal diseases, has completed the first part of a randomized,…

Read More
23 Jul 2018
Oncostellae initiated clinical development of OST-122


febrero 24, 2019

Oncostellae has started today a first-in-human study of OST-122, its novel, gut-restricted Jak3/Tyk2 inhibitor that is being developed for the local…

Read More
22 Feb 2019
IO4COLON Project Presentation


febrero 23, 2019

Last 22th of February at 12:00 pm was celebrated the Presentation of IO4COLON Project in the CIQUS Research Center We are pleased…

Read More
25-27 Sep 2018
Oncostellae participates at Biospain 2018 in Seville


julio 19, 2018

Oncostellae participates at the 2018 Biospain congress that takes place from 25th to 27th of September  2018  in the Fibes Exhibition &…

Read More
02 Jul 2018
Neogalfarm Project Results



julio 2, 2018

Nuevos fármacos contra el cáncer: Desarrollo de terapias dirigidas a diferentes dianas terapéuticas y de tratamientos combinados Período de ejecución: Febrero…

Read More
4-7 June 2018
Oncostellae participates at the 2018 Bio International Convention in Boston

junio 12, 2018

Boston, 4-7 June 2018. Guido Kurz, CEO of Oncostellae, attends the Bio International Convention that takes place on June 4-7, 2018…

Read More
14 Feb 2017
Cuatro biotecnológicas gallegas se alían en una plataforma para buscar nuevos fármacos contra el cáncer
febrero 14, 2016

GalChimia, AMSLab, Oncostellae y Nanogap presentan Neogalfarma, que aspira a diseñar, sintetizar y evaluar biológicamente nuevas moléculas antitumorales Cuatro empresas gallegas…

Read More